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International Circumpolar Surveillance (ICS) is a popu-
lation-based invasive bacterial disease surveillance net-
work. Participating Canadian regions include Yukon, North-
west Territories, Nunavut, and northern regions of Québec 
and Labrador (total population 132,956, 59% aboriginal). 
Clinical and demographic information were collected by us-
ing standardized surveillance forms. Bacterial isolates were 
forwarded to reference laboratories for conﬁ  rmation  and 
serotyping. After pneumococcal conjugate vaccine intro-
duction, crude annual incidence rates of invasive Strepto-
coccus pneumoniae decreased from 34.0/100,000 popula-
tion (1999–2002) to 23.6/100,000 population (2003–2005); 
substantial reductions were shown among aboriginals. 
However, incidence rates of S. pneumoniae, Haemophilus 
inﬂ  uenzae, and group A streptococci were higher in ab-
original populations than in non-aboriginal populations. H. 
inﬂ  uenzae type b was rare; 52% of all H. inﬂ  uenzae cases 
were caused by type a. Data collected by ICS contribute to 
the understanding of the epidemiology of invasive bacte-
rial diseases among northern populations, which assists in 
formulation of prevention and control strategies, including 
immunization recommendations.
T
he circumpolar region of Canada is a sparsely popu-
lated area of 1.74 million square miles comprising 3 
territories (Yukon, Northwest Territories, and Nunavut) 
and the northern regions of Québec and Labrador. The es-
timated population is 132,956, which represents 0.4% of 
the Canadian population (1). The circumpolar population is 
younger (Table 1) and has a larger proportion of aboriginal 
persons than the general Canadian population. Approxi-
mately 59% of the population in the region self-identify as 
Inuit, First Nations, or Métis, compared with 3.3% of the 
total Canadian population (2). Northern populations tend to 
have higher rates of invasive bacterial diseases, including 
those caused by Streptococcus pneumoniae and Haemophi-
lus inﬂ  uenzae, with aboriginal persons at greatest risk for 
disease (3–5).
Canada has a universal healthcare system that includes 
access to both physician and hospital care. Publicly funded 
vaccination programs are a major component of disease 
control programs. Universal infant H.  inﬂ  uenzae type b 
(Hib) vaccination programs were implemented in the Yu-
kon, Northwest Territories, Nunavut, and northern regions 
of Québec and Labrador in the early 1990s. Pneumococcal 
polysaccharide vaccine, which protects against 23 sero-
types of S. pneumoniae, has been available since 1983 and 
is recommended by the Canadian National Advisory Com-
mittee on Immunization (NACI) for all adults >65 years of 
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age and children >2 years of age at high risk for infection. 
The 7-valent pneumococcal conjugate vaccine (PCV7) 
protects against 7 serotypes of S. pneumoniae and has been 
available in Canada since 2001; NACI recommends it for 
all children <2 years of age and children <5 years of age 
at high risk for disease. Meningococcal C conjugate vac-
cine has been recommended by NACI for all children <5 
years of age, adolescents, and young adults since 2001 (6). 
Implementation of these NACI recommendations has oc-
curred at various times throughout the region.
In Canada, communicable disease reporting is mandat-
ed at the provincial or territorial level; the list of reportable 
diseases varies by region. Reporting to national notiﬁ  able 
disease surveillance is not mandatory, and timely submis-
sion of case-by-case data with epidemiologic, clinical, and 
laboratory information is variable. Therefore, to increase 
the understanding of the epidemiology of invasive bacterial 
diseases in northern populations, Canada has participated 
in International Circumpolar Surveillance (ICS) since its 
inception in 1999. ICS is a population-based invasive bac-
terial disease surveillance network of circumpolar coun-
tries that includes the United States, Canada, Greenland, 
Iceland, Finland, Norway, and Sweden. We describe Cana-
dian ICS data from 1999 through 2005, including the effect 
of universal PCV7 programs on invasive S. pneumoniae 
disease in children <2 years of age.
Methods
Case Reporting and Data Collection
Surveillance of invasive disease caused by S.  pneu-
moniae began January 1, 1999. Surveillance for invasive H. 
inﬂ  uenzae, group A streptococci (GAS), group B strepto-
cocci (GBS), and Neisseria meningitidis commenced Janu-
ary 1, 2000. Cases reportable to ICS are deﬁ  ned as persons 
from whom an organism under surveillance is isolated from 
blood, cerebrospinal ﬂ  uid, or other normally sterile site. Pa-
tients with clinical epiglottitis from whom H. inﬂ  uenzae is 
isolated from an epiglottis swab are also reportable to ICS. 
Cases are reported to public health ofﬁ  cials by physicians 
or laboratories serving regions under surveillance; this in-
cludes patients managed outside of the region. Unconﬁ  rmed 
cases are not included. Standardized case report forms are 
completed in the region by trained communicable disease 
ofﬁ  cers and include demographic, clinical, vaccination, and 
risk factor information. For the vaccine-preventable diseases 
(caused by S. pneumoniae, Hib, and N. meningitidis), details 
on the type of vaccine received are not currently available; 
however, information on the number of doses received is 
available. Reference laboratory representatives and com-
municable disease ofﬁ  cers from each region participate in 
quarterly and annual data audits to ensure completeness of 
case ﬁ  nding and reporting.
Laboratory Methods
A network of laboratories ascertains infection with any 
of the 5 organisms under surveillance within the region. 
Invasive isolates are submitted to 1 of 3 Canadian reference 
laboratories (National Centre for Streptococcus, National 
Microbiology Laboratory, and Laboratoire de Santé Pub-
lique du Québec). The reference laboratory conﬁ  rms the 
isolate’s identity, determines its serotype or serogroup, and 
tests for antimicrobial susceptibility. Laboratories also par-
ticipate in an ongoing quality control program.
Isolates were conﬁ  rmed as S. pneumoniae by using 
conventional methods of identiﬁ  cation (7). Strains were 
classiﬁ  ed by the capsular swelling technique (8,9) by using 
commercial antisera (Statens Serum Institut, Copenhagen, 
Denmark). Antimicrobial drug susceptibility testing was 
performed by using the broth microdilution method consis-
tent with National Committee for Clinical Laboratory Stan-
dards guidelines current at the time of testing (10,11).
M typing was performed on all submitted GAS isolates 
according to standardized methods (12) by using M type–
speciﬁ  c antisera prepared in-house. Antisera to 61 of 86 
internationally recognized M types, representing the most 
common M types (13), were available; strains for which 
an M type could not be assigned were classiﬁ  ed as M non-
typeable. GBS serotyping was performed according to con-
ventional serologic techniques (14) by using type-speciﬁ  c 
antisera prepared in-house. Antisera were available for all 
9 internationally recognized serotypes (Ia, Ib, II, III, IV, V, 
VI, VII, and VIII). For both organisms, Lanceﬁ  eld hot-acid 
extracts were prepared from the clinical isolates and tested 
in Ouchterlony immunodiffusion agar slides with appropri-
ate control strains.
H. inﬂ  uenzae was conﬁ  rmed by standard biochemi-
cal tests (15), and biotypes were determined according to 
current nomenclature (16). Serotyping was conducted by 
using a slide agglutination assay with antisera from com-
mercial sources (Difco, Oakville, Ontario, Canada, and 
Denka Seiken, Tokyo, Japan). N. meningitidis was identi-
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Table 1. Total and age-specific population estimates for the Canadian circumpolar region and entire population, 2001 census (1)
Age, no. (%) 
Region Total <2 y  2–4 y  5–19 y  20–64 y  >65 y 
Circumpolar* 132,956 4,849 (3.7)  7,414 (5.6)  37,431 (28.2)  77,823 (58.5)  5,439 (4.1) 
Canada† 30,007,095 652,120 (2.2)  1,044,160 (3.5)  6,082,585 (20.3)  18,339,680 (61.1)  3,888,550 (13.0) 
*Yukon, Northwest Territories, Nunavut, northern Québec, and northern Labrador. 
†Includes the circumpolar region. INTERNATIONAL POLAR YEAR  RESEARCH
ﬁ  ed by using standard biochemical tests (17). Serogrouping 
was conducted by using bacterial agglutination with rabbit 
antisera to the different serogroups. Serotyping and sero-
subtyping were conducted by using an indirect, whole-cell, 
ELISA with monoclonal antibodies (18).
Statistical Analysis
Statistical analysis was conducted by using SAS sta-
tistical package version 9.1 (SAS, Cary, NC, USA). The 
analyses were stratiﬁ  ed by organism. Crude and age-spe-
ciﬁ  c annual incidence was calculated by using total and 
age-speciﬁ  c population estimates from the Demography 
Division of Statistics Canada for 2001 (1). Because of the 
small numbers of cases per year, 3-year period–based an-
nual incidence rates were calculated for each organism to 
determine time trends. Rates were calculated for 2 periods 
(1999 for S. pneumoniae or 2000 for H. inﬂ  uenzae, GAS, 
and GBS to 2002 and 2003–2005). Regression analysis was 
conducted to detect trends in crude annual incidence rates 
over time. Crude incidence rates by ethnicity were calculat-
ed by using population data from the aboriginal population 
proﬁ  le, which was developed from 2001 census data (2). 
Because of the lack of additional period estimates, no trend 
analyses were conducted on data by ethnicity.
Information about PCV7 program implementation was 
collected from the regions (Table 2). The prevaccination 
period was deﬁ  ned as 1999–2002, and the program im-
plementation period was deﬁ  ned as 2003–2005. Because 
Labrador implemented its vaccination program during the 
second period, data from this region on the effect of the 
vaccine were excluded from the analysis. Sensitivity anal-
yses that included data from Labrador in both arms was 
conducted to ensure this did not alter the results. Annual 
incidence of S. pneumoniae for all ages and the number of 
cases in children <2 years of age were compared for the 2 
periods. Bivariate analysis was conducted by using χ2 and 
Fisher exact tests.
Results
There were 251 conﬁ  rmed cases of invasive disease 
caused by S. pneumoniae in northern Canada from 1999 
through 2005. During 2000–2005, 62 cases of invasive dis-
ease caused by H. inﬂ  uenzae, 45 caused by GAS, 17 caused 
by GBS, and 6 caused by N. meningitidis were reported. 
Because of the small number of N. meningitidis cases re-
ported, no further disease-speciﬁ  c analyses were conducted 
for this organism.
Cases and Incidence Rates
In the ICS region, the crude annual incidence rate for 
S. pneumoniae was highest in 2001 (38.4/100,000 popula-
tion) and lowest in 2005 (17.3/100,000 population), but this 
downward trend was not statistically signiﬁ  cant (p = 0.119 
by F test for slope). The age-speciﬁ  c incidence rate in chil-
dren <2 years of age decreased during 2000–2004 but in-
creased in 2005. However, these incidence rates are based 
on a small number of cases and changes in rates over time 
should be interpreted with caution. The incidence rates in 
the population >65 years of age, who were eligible for the 
23-valent polysaccharide vaccination, did not show any 
trend (Table 3). During 1999–2002 and 2003–2005, the 
crude annual incidence rates were 34.0 and 23.6/100,000 
population/year, respectively. Although this ﬁ  nding sug-
gests a decreasing incidence over the 2 periods, data from 
additional periods are necessary to determine if this is re-
ﬂ  ective of a trend.
Among the 240 (95.6%) of 251 S. pneumoniae cases 
with serotype information, the most common serotypes 
were type 1 (30.4%), type 8 (8.8%), type 14 (7.9%), type 
4 (6.3%), and type 6B (5.8%). A total of 47 (60%) of 52 
cases in children <2 years of age were caused by PCV7 
serotypes. Among persons >65 years of age, 23 (88.5%) 
of 26 cases were caused by serotypes in the polysaccharide 
pneumococcal vaccine.
There were no trends in overall crude annual inci-
dence rates of H. inﬂ  uenzae or GBS (Table 4). The crude 
annual incidence rate of H. inﬂ  uenzae was lowest in 2003 
(4.5/100,000 population) and highest in 2001 (13.5/100,000 
population). Among 59 cases with serotype information, 
31 (59%) were H. inﬂ  uenzae type a (Hia); 73.3% of these 
cases were in children <2 years of age. Eight cases (13.6%) 
of Hib were reported during the surveillance period: 6 in 
infants <5 months of age, 1 in a child 18 months of age, and 
1 in an adult. Two infants had no vaccine information. The 
adult and 1 infant had not been vaccinated; the remaining 4 
children had received only 1 Hib dose. Thus, none of these 
cases were considered vaccine failures. GAS incidence in-
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Table 2. Implementation dates of infant vaccination programs with 
universal 7-valent pneumococcal conjugate vaccine, by 
circumpolar region, Canada 
Region Date
Northern Québec  Apr 2002 
Nunavit Sep 2002
Northern Labrador  Jul 2003 
Yukon Jun 2005
Northwest Territories  Jan 2006 
Table 3. Crude annual incidence of Streptococcus pneumoniae in 
the Canadian circumpolar region by age group, 1999–2005 
Incidence/100,000 population (no. cases) 
Year  Total population  Age <2 y  Age >65 y 
1999 25.6 (34)  226.9 (11)  55.2 (3) 
2000 33.8 (45)  226.9 (11)  36.8 (2) 
2001 38.4 (51)  165.0 (8)  91.9 (5) 
2002 26.3 (35)  123.7 (6)  73.5 (4) 
2003 22.6 (30)  103.1 (5)  110.3 (6) 
2004 24.8 (33)  61.9 (3)  36.8 (2) 
2005 17.3 (23)  165.0 (8)  73.5 (4) Invasive Bacterial Diseases in Northern Canada
creased signiﬁ  cantly during 2001–2005 (F = 229.371, p = 
0.01). The largest number of cases (n = 14) was reported 
in 2005 with a crude incidence rate of 10.5/100,000 pop-
ulation. The increase in GAS cases was not clustered by 
region, period, or serotype. A total of 1–4 cases of GBS 
were reported in the region annually, for a crude annual 
incidence range of 0.8–3.0/100,000 population.
Demographic Characteristics
Infections with S.  pneumoniae,  H.  inﬂ  uenzae, and 
GAS were more common in male patients (59.8%, 58.3%, 
and 62.2%, respectively). Seventy-one percent of all cases 
of GBS were among female patients; 17.6% (3/17) of cases 
of GBS were among newborns <1 month of age. All of the 
newborn cases occurred in the early neonatal period. These 
4 organisms disproportionately affect children <2 years of 
age and persons >65 years of age. Although <4% of the sur-
veillance population was <2 years of age, 21%–67% of the 
infections occurred within this age group. Similarly, adults 
>65 years of age had a higher proportion of cases than the 
surveillance population they represent (Figure).
Data on patient ethnicity was missing for 42 (11.0%) of 
381 cases of invasive bacterial disease. Aboriginal persons 
represented 59% of the surveillance population and 84% 
of cases of S. pneumoniae, 92% of H. inﬂ  uenzae, 93% of 
GAS, and 53% of GBS. To assess changing incidence over 
time by ethnicity, the surveillance period was divided into 
2 periods (1999–2002 and 2003–2005 for S. pneumoniae 
and 2000–2002 and 2003–2005 for all other organisms). 
For all but GBS, the crude annualized incidence rates were 
higher in the aboriginal population than in the non-aborigi-
nal population (Table 5). For S. pneumoniae, the dispar-
ity between aboriginal persons and non-aboriginal persons 
decreased from 4.6-fold to 2.5-fold between the 2 periods. 
Among aboriginal persons, the GAS rate in the second pe-
riod was nearly double that seen in the ﬁ  rst period. Six of 8 
case-patients with Hib and all 27 case-patients with Hia for 
whom ethnicity data were available were among aboriginal 
persons.
Clinical Findings and Outcomes
Information on clinical ﬁ  ndings was available for 380 
of 381 cases (Table 6). The most common primary clinical 
ﬁ  nding for invasive S. pneumoniae was pneumonia (64.5%), 
followed by bacteremia/septicemia (21.5%). Among inva-
sive GAS cases, the most common primary clinical ﬁ  nding 
was cellulitis (31.1%); necrotizing fasciitis accounted for 
11.1%. For cases with H. inﬂ  uenzae or GBS, the most com-
mon primary clinical ﬁ  ndings were bacteremia/septicemia 
(33.9% and 47.1%, respectively). There were no reported 
cases of epiglottitis caused by H. inﬂ  uenzae.
Cases with GAS had the highest case-fatality rate 
(18.2%, 8 of 44 cases with outcome data). Two (40%) of 5 
cases with GAS and necrotizing fasciitis resulted in death; 
however, this difference was not statistically signiﬁ  cant (p 
= 0.065, by Fisher exact test). The case-fatality rates for 
infections with the other 3 organisms were 4.8% (11/230) 
for S. pneumoniae, 6.1% (3/49) for H. inﬂ  uenzae, and 7.1% 
(1/14) for GBS. The relative risk for death did not vary by 
ethnicity (p = 0.550, by Fisher exact test).
Effect of PCV7 Immunization Programs
Fifty-two cases of S. pneumoniae occurred in children 
<2 years of age. Eight of these case-patients had received 
>1 dose of pneumococcal vaccination: 1 case-patient with 
of PCV7-preventable S. pneumoniae had received only 1 
dose of vaccine (serotype 6b), 6 case-patients had serotypes 
that were not preventable with PCV7 (serotypes 19A, 20, 
13, 15a, 22, and 22F), and 1 case-patient had no informa-
tion on serotype. These ﬁ  ndings suggest that there were no 
known cases of vaccine failure.
Numbers of cases of disease caused by S. pneumoniae 
in children <2 years of age were compared during the pre-
vaccination and program implementation periods (Table 
7). In regions where universal PCV7 infant programs were 
implemented in 2002 (Nunavut and northern Québec), 19 
cases with PCV7 serotypes were reported during the pre-
vaccination period and no cases were reported during the 
program implementation period. In the other Canadian ICS 
regions where universal PCV7 infant programs were imple-
mented after 2002 (excluding Labrador), 6 cases of PCV7-
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Table 4. Crude annual incidence of Haemophilus influenzae,
GAS, and GBS in the Canadian circumpolar region, 2000–2005* 
Incidence/100,000 population (no. cases) 
Year  H. influenzae GAS GBS 
2000 6.0 (8)  5.3 (7)  3.0 (4) 
2001 13.5 (18)  1.5 (2)  3.0 (4) 
2002 6.0 (8)  3.8 (5)  1.5 (2) 
2003 4.5 (6)  5.3 (7)  3.0 (4) 
2004 8.3 (11)  7.5 (10)  1.5 (2) 
2005 8.3 (11)  10.5 (14)  0.8 (1) 
*GAS, group A streptococci; GBS, group B streptococci. 
Figure. Age distribution of surveillance population and cases of 
infection with group B streptococci (GBS), group A streptococci 
(GAS), Haemophilus inﬂ  uenzae, and Streptococcus pneumoniae 
in the Canadian circumpolar region.INTERNATIONAL POLAR YEAR  RESEARCH
preventable S. pneumoniae disease occurred in the prevac-
cination period and 3 cases in the program implementation 
period. A χ2 analysis showed that the number of cases of 
PCV7-preventable illness by vaccination region was statis-
tically signiﬁ  cant (p = 0.019, by Fisher exact test). These 
results are conservatively biased because PCV7 was avail-
able in all regions in the program implementation period 
and a universal vaccination program was started during the 
later half of 2005 in the Yukon, which may have reduced 
the number of cases seen in the comparison area. Our ﬁ  nd-
ings suggest that early implementation of universal PCV7 
programs was associated with a reduction in PCV7-prevent-
able illness in children <2 years of age. A sensitivity analysis 
including Labrador in both arms (program or no program) 
did not change the statistical signiﬁ  cance of the difference 
because 1 case in Labrador was not vaccine preventable.
Discussion
To our knowledge, this study is the ﬁ  rst comprehensive 
surveillance report on invasive bacterial diseases in the Ca-
nadian Arctic. Disease caused by S. pneumoniae continues 
to be a serious problem in northern Canada. The annual rate 
for 2003–2005 was 23.6/100,000 population/year, which is 
more than twice the reported rate of invasive pneumococ-
cal disease in the overall Canadian population (9.1/100,000 
population in 2004) (19). Although this rate is lower than 
that seen in the earlier period (1999–2002, 34.0/100,000 
population), additional data will be needed to determine if 
the decreasing trend is sustained. The decrease in the dis-
ease incidence may be partly attributed to PCV7 programs, 
as well as the mass pneumococcal polysaccharide vacci-
nation campaigns launched in 2001 and 2002 in response 
to outbreaks of serotype 1 disease in parts of the region, 
which reduced the occurrence of this predominant serotype 
in subsequent years (20,21). Reduction in the number of 
cases among children <2 years of age in regions where uni-
versal infant PCV7 programs were implemented in 2002 
(northern Québec and Nunavut) is an early indicator of the 
effect of the vaccination program. This ﬁ  nding is likely a 
conservative assessment of the effect of the program, given 
the staggered implementation of universal vaccine pro-
grams in the circumpolar region.
Although aboriginal persons represented 84% of inva-
sive S. pneumoniae cases, a substantial reduction in disease 
incidence was demonstrated in the program implementa-
tion period. Progress toward elimination of this health dis-
parity has also been reported for indigenous populations 
in Alaska (22) and Australia (23), where PCV7 has been 
available since 2001 to all indigenous children <2 years of 
age. The incidence of S. pneumoniae may be expected to 
decrease further among young children throughout north-
ern Canada, particularly in aboriginal children, as universal 
PCV7 programs become fully implemented with sustained 
high coverage rates.
In contrast, there continues to be a health disparity for 
invasive H. inﬂ  uenzae disease. Annual period incidence 
rates for H.  inﬂ  uenzae during 2003–2005 were >4-fold 
higher among aboriginal persons than among non-aborigi-
nal persons. Although Hib disease is rare because of uni-
versal Hib vaccination, the greatest number of cases oc-
curred among aboriginal persons, a group known to be at 
increased risk for Hib disease (24–26). Studies in Alaskan 
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Table 5. Crude annualized incidence of Streptococcus 
pneumoniae, Haemophilus influenzae, GAS, and GBS by  
ethnicity in the Canadian circumpolar region, 1999–2005* 
Incidence/100,000 population/ 
year (no. cases) 
Organism, ethnicity  1999–2002 2003–2005
S. pneumoniae
Non-aboriginal 9.6  (20)  10.2  (16) 
Aboriginal 44.2 (134)  25.1 (57) 
2000–2002 2003–2005
H. influenzae
Non-aboriginal 0.6  (1)  1.9  (3) 
Aboriginal 11.9 (27)  8.4 (19) 
GAS
Non-aboriginal 0 1.9 (3)
Aboriginal 5.7 (13)  11.0 (25) 
GBS
Non-aboriginal 2.6  (4)  1.9  (3) 
Aboriginal 2.2 (5)  1.3 (3) 
*GAS, group A streptococci; GBS, group B streptococci.  
Table 6. Primary clinical symptoms for patients infected with Streptococcus pneumoniae, Haemophilus influenzae, GAS, or GBS in the 
Canadian circumpolar region* 
Symptoms 
S. pneumoniae  (n = 251), 
no. (%) 
H. influenzae (n = 62), 
no. (%)
GAS (n = 44),†  
no. (%)  
GBS (n = 17),  
no. (%) 
Septicemia/bacteremia 21.5 (54)  33.9 (21)  22.7 (10)  47.1 (8) 
Pneumonia 64.5 (162)  21.0 (13)  13.6 (6)  0
Meningitis 6.0 (15)  27.4 (17)  0 11.8 (2) 
Cellulitis 0.8 (2)  4.8 (3)  31.8 (14)  11.8 (2) 
Empyema  3.2 (8)  3.23 (2)  2.3 (1)  0
Necrotizing fasciitis  0 0 11.4 (5)  0
Septic arthritis  0.8 (2)  4.8 (3)  9.1 (4)  17.7 (3) 
Other‡  3.2 (8)  4.8 (3)  9.1 (4)  11.8 (2) 
*GAS, group A streptococci; GBS, group B streptococci.  
†One patient had no information recorded for clinical symptoms. 
‡Includes peritonitis, appendicitis, pericarditis, osteomyelitis, and endocarditis. Invasive Bacterial Diseases in Northern Canada
aboriginal populations suggest that continued low-level 
nasopharangeal colonization facilitates transmission to 
susceptible children (4). Environmental and housing con-
ditions, including overcrowding, are also potential contrib-
uting factors to these health disparities (27–29). The data 
also indicate an apparent emergence of type a disease, with 
all Hia cases occurring among aboriginal persons. Hia dis-
ease has also been reported in aboriginal populations in the 
United States and Australia (30–32). A possible shift in dis-
ease epidemiology to non-b serotypes has been suggested 
from ﬁ  ndings in an adjacent Canadian region (33), whereas 
a sustained increase in non-b serotypes has not been de-
tected in Alaska (4).
The incidence of GAS in the ICS region has been in-
creasing since 2001. Although changes in rates over time 
should be interpreted with caution because the number of 
cases is small, this apparent increase in GAS disease is be-
ing monitored. The rate in northern regions is greater than 
that in the overall Canadian population. In 2004, the inci-
dence of GAS in the ICS population was 7.5 compared with 
the Canadian rate of 2.7/100,000 population (Public Health 
Agency of Canada, unpub. data). Aboriginal persons repre-
sented the greatest proportion of GAS cases; this has also 
been observed among indigenous populations in the United 
States (34) and Australia (35). As with S. pneumoniae and 
H. inﬂ  uenzae, this may be partially attributed to poverty 
and crowded living conditions in these populations (36).
A major limitation of the data is that the number of re-
ported cases is too small to permit analysis of smaller areas 
and subpopulations within the region. In addition, changes 
in rates over time should be interpreted with caution due to 
small numbers of cases. It is also expected that the number 
of reported cases of invasive bacterial diseases is an under-
estimate. However, the enhanced nature of the surveillance 
system and regular data audits represent improvements over 
routine passive surveillance. Laboratory specimens may 
not have been taken before initiation of empiric treatment, 
and collection and transportation of clinical specimens are 
difﬁ  cult in remote areas experiencing extreme temperatures 
(20,21). Unfortunately, because vaccine registries have not 
yet been fully implemented in Canada, immunization cov-
erage rates are not available. This situation limits our abil-
ity to evaluate the effect of vaccination programs.
Despite these limitations, data collected by ICS con-
tribute to understanding the epidemiology of invasive bac-
terial diseases among northern populations in Canada and 
throughout the world. These data assist in formulation of 
prevention and control strategies, including immunization 
recommendations (6). ICS data have also been instrumental 
in identifying potentially emerging pathogens such as Hia. 
Continued collection of data will be used to assess the ef-
fect of vaccination in this population and monitor serotype 
replacement, antimicrobial drug resistance, and reductions 
in disparities in Northern populations.
Dr Degani works at the Child Health Evaluative Sciences 
Unit at the Hospital for Sick Children in Toronto, Canada. Her 
research interests include infectious diseases and their prevention 
in marginalized populations.
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